Orally Available Therapies


The development of oral medications provides convenience and improved patient adherence compared to traditional injection or infusion therapies.


Myrobalan’s focus on developing orally available small molecule neurorestorative therapies reflects a broader trend in the pharmaceutical industry. The specific targeting of GPR17 by Myrobalan indicates a trend in precision medicine and personalized therapies. Companies are increasingly identifying specific molecular targets to address the underlying causes of diseases, such as promoting remyelination in neurological conditions. Funding $24 million.



Related Trends